BLAINJECTIONINJECTABLE
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUFLYMA (adalimumab-aaty) is a biosimilar monoclonal antibody approved in May 2023 that targets TNF-alpha to reduce inflammatory responses. It is indicated for multiple autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and others where TNF inhibition is therapeutic. The drug works by binding and neutralizing TNF-alpha, a key inflammatory cytokine driving disease pathogenesis.
Growth
Newly approved biosimilar entering growth phase with moderate competitive pressure, suggesting expanding commercial infrastructure and field-based team opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Yuflyma® (Adalimumab), Patient Experience After Switching
Started Jun 2022
300 enrolled
Rheumatoid ArthritisAnkylosing SpondylarthritisAxial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis+3 more
Career Relevance
YUFLYMA represents a high-velocity commercial opportunity in the high-volume TNF-inhibitor market, requiring strong sales execution, payer negotiation, and patient access expertise. Careers on this product emphasize rapid market share capture, geographic expansion, and competitive pricing strategy rather than clinical innovation.
Brand Manager
Worked on YUFLYMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.